Panbela Therapeutics Inc.

01/26/2022 | Press release | Distributed by Public on 01/26/2022 08:06

Panbela Initiates a Randomized, Double-Blind, Placebo-Controlled Study (ASPIRE) of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for[...]